22,281 results match your criteria mAbs [Journal]


Single cell-produced and in vitro-assembled anti-FcRH5/CD3 T-cell dependent bispecific antibodies have similar in vitro and in vivo properties.

MAbs 2018 Dec 14. Epub 2018 Dec 14.

a Genentech, Inc ., South San Francisco , CA , USA.

Bispecific antibody production using single host cells has been a new advancement in the antibody engineering field. We previously showed comparable in vitro biological activity and in vivo mouse pharmacokinetics (PK) for two novel single cell variants (v10 and v11) and one traditional dual cell in vitro-assembled anti-human epidermal growth factor receptor 2/CD3 T-cell dependent bispecific (TDB) antibodies. Here, we extended our previous work to assess single cell-produced bispecific variants of a novel TDB against FcRH5, a B-cell lineage marker expressed on multiple myeloma (MM) tumor cells. Read More

View Article
December 2018

Anti-tumor effects of antibodies to L-type amino-acid transporter 1 (LAT1) bound to human and monkey LAT1 with dual avidity modes.

Cancer Sci 2018 Dec 10. Epub 2018 Dec 10.

Cell Biology Laboratory, School of Pharmacy, Kindai University, Osaka, Japan.

L-type amino-acid transporter 1 (LAT1) disulfide-linked to the CD98 heavy chain (hc) is highly expressed in most cancer cells, but weakly expressed in normal cells. In this study, we developed novel anti-LAT1 mAbs, and demonstrated the internalization activity, inhibitory effects of amino acid uptake and cell growth and antibody-dependent cellular cytotoxicity, as well as in vivo anti-tumor effects in athymic mice. Furthermore, we examined the reactivity of mAbs with LAT1 of Macaca fascicularis to evaluate possible side effects of anti-human LAT1 mAbs in clinical trials. Read More

View Article
December 2018

Administration of Subcutaneous Monoclonal Antibodies in Patients With Cancer.

Oncol Nurs Forum 2019 Jan;46(1):E38-E47

National Cancer Institute in Rio de Janeiro, Brazil.

Problem Identification: Subcutaneous (SC) formulations for monoclonal antibodies (mAbs) must be evaluated for efficacy and safety in comparison with preexisting IV formulations to identify potential benefits and risks.

Literature Search: This is a systematic review of clinical trials. MEDLINE®/PubMed, EMBASE, Cochrane Library, LILACS (Latin American and Caribbean Health Sciences Literature), and reference lists were searched for relevant studies. Read More

View Article
January 2019

CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma.

Front Immunol 2018 28;9:2722. Epub 2018 Nov 28.

Laboratory of Immunogenetics, Department of Medical Sciences, University of Torino, Torino, Italy.

Multiple Myeloma (MM) is a hematological cancer characterized by proliferation of malignant plasma cells in the bone marrow (BM). MM represents the second most frequent hematological malignancy, accounting 1% of all cancer and 13% of hematological tumors, with ~9,000 new cases per year. Patients with monoclonal gammopathy of undetermined significance (MGUS) and asymptomatic smoldering MM (SMM) usually evolve to active MM in the presence of increased tumor burden, symptoms and organ damage. Read More

View Article
November 2018

Membrane and Cytoplasmic Proteins of subspecies that Bind to Novel Monoclonal Antibodies.

Microorganisms 2018 Dec 11;6(4). Epub 2018 Dec 11.

Ruminant Diseases Immunology Research Unit, National Animal Disease Center, USDA-Agricultural Research Service, Ames, IA 50010, USA.

Monoclonal antibodies against subspecies proteins are important tools in Johne's disease research and diagnostics. Johne's disease is a chronic inflammatory intestinal disease of cattle, sheep, and other ruminant animals. We have previously generated multiple sets of monoclonal antibodies (mAbs) in different studies; however, because many were generated and screened against a whole-cell extract of , the antigens that bind to these antibodies remained unknown. Read More

View Article
December 2018
1 Read

Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update.

Int J Mol Sci 2018 Dec 7;19(12). Epub 2018 Dec 7.

Department of Pharmaceutical Sciences, Wayne State University, Detroit, MI 48202, USA.

The past two decades have seen a revolution in multiple myeloma (MM) therapy with the introduction of several small molecules, mostly orally effective, whose mechanisms are based on proteasome inhibition, histone deacetylase (HDAC) blockade, and immunomodulation. Immunotherapeutic approaches to MM treatment using monoclonal antibodies (mAbs), while long in development, began to reap success with the identification of CD38 and SLAMF7 as suitable targets for development, culminating in the 2015 Food and Drug Administration (FDA) approval of daratumumab and elotuzumab, respectively. This review highlights additional mAbs now in the developmental pipeline. Read More

View Article
December 2018
1 Read

Structure, heterogeneity and developability assessment of therapeutic antibodies.

MAbs 2018 Dec 13. Epub 2018 Dec 13.

c Product Characterization , Alexion Pharmaceuticals, Inc ., New Haven , CT , USA.

Increasing attention has been paid to developability assessment with the understanding that thorough evaluation of monoclonal antibody lead candidates at an early stage can avoid delays during late-stage development. The concept of developability is based on the knowledge gained from the successful development of approximately 80 marketed antibody and Fc-fusion protein drug products and from the lessons learned from many failed development programs over the last three decades. Here, we reviewed antibody quality attributes that are critical to development and traditional and state-of-the-art analytical methods to monitor those attributes. Read More

View Article
December 2018

CTLA-4 and PD-1 Control of T-Cell Motility and Migration: Implications for Tumor Immunotherapy.

Front Immunol 2018 27;9:2737. Epub 2018 Nov 27.

Research Center-Maisonneuve-Rosemont Hospital (CRHMR), Montreal, QC, Canada.

CTLA-4 is a co-receptor on T-cells that controls peripheral tolerance and the development of autoimmunity. Immune check-point blockade (ICB) uses monoclonal antibodies (MAbs) to block the binding of inhibitory receptors (IRs) to their natural ligands. A humanized antibody to CTLA-4 was first approved clinically followed by the use of antibody blockade against PD-1 and its ligand PD-L1. Read More

View Article
November 2018

Equine-origin immunoglobulin fragments protects nonhuman primates from Ebola virus disease.

J Virol 2018 Dec 12. Epub 2018 Dec 12.

National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada

Ebola virus (EBOV) infections result in aggressive hemorrhagic fever in humans with fatality rates reaching 90%, with no licensed, specific therapeutics to treat ill patients. Advances over the past 5 years have firmly established monoclonal antibody (mAb)-based products as the most promising therapeutics for treating EBOV infections, but production is costly, quantities are limited, and thus mAbs are not the best candidates for mass use in the case of an epidemic. To address this need, we generated EBOV-specific polyclonal immunoglobulin fragments F(ab') from horses hyperimmunized with an EBOV vaccine. Read More

View Article
December 2018
1 Read

Human Norovirus Neutralized by a Monoclonal Antibody Targeting the HBGA Pocket.

J Virol 2018 Dec 12. Epub 2018 Dec 12.

Schaller Research Group at the University of Heidelberg and the DKFZ, Heidelberg, Germany

Temporal changes in the GII.4 human norovirus capsid sequences occasionally result in the emergence of genetic variants capable of causing new epidemics. The GII. Read More

View Article
December 2018

Development of stable rotavirus reporter expression systems.

J Virol 2018 Dec 12. Epub 2018 Dec 12.

Department of Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan

Engineered recombinant viruses expressing reporter genes have been developed for real-time monitoring of replication and for mass screening of anti-viral inhibitors. Recently, we reported using a reverse genetics system to develop the first recombinant reporter rotaviruses (RVs) that expressed NanoLuc (NLuc) luciferase. Here, we describe a strategy for developing stable reporter RVs expressing luciferase and green or red fluorescent proteins. Read More

View Article
December 2018

Anti-PD1 'SHR-1210' aberrantly targets pro-angiogenic receptors and this polyspecificity can be ablated by paratope refinement.

MAbs 2018 Dec 12:1-19. Epub 2018 Dec 12.

a UltraHuman Limited, Codebase , Edinburgh , UK.

Monoclonal anti-programmed cell death 1 (PD1) antibodies are successful cancer therapeutics, but it is not well understood why individual antibodies should have idiosyncratic side-effects. As the humanized antibody SHR-1210 causes capillary hemangioma in patients, a unique toxicity amongst anti-PD1 antibodies, we performed human receptor proteome screening to identify nonspecific interactions that might drive angiogenesis. This screen identified that SHR-1210 mediated aberrant, but highly selective, low affinity binding to human receptors such as vascular endothelial growth factor receptor 2 (VEGFR2), frizzled class receptor 5 and UL16 binding protein 2 (ULBP2). Read More

View Article
December 2018

In vitro and in silico assessment of the developability of a designed monoclonal antibody library.

MAbs 2018 Dec 7. Epub 2018 Dec 7.

a Large Protein Biophysics , Novo Nordisk A/S , Måløv , Denmark.

Despite major advances in antibody discovery technologies, the successful development of monoclonal antibodies (mAbs) into effective therapeutic and diagnostic agents can often be impeded by developability liabilities, such as poor expression, low solubility, high viscosity and aggregation. Therefore, strategies to predict at the early phases of antibody development the risk of late-stage failure of antibody candidates are highly valuable. In this work, we employ the in silico solubility predictor CamSol to design a library of 17 variants of a humanized mAb predicted to span a broad range of solubility values, and we examine their developability potential with a battery of commonly used in vitro and in silico assays. Read More

View Article
December 2018

Physiologically-based modeling of monoclonal antibody pharmacokinetics in drug discovery and development.

Drug Metab Pharmacokinet 2018 Nov 22. Epub 2018 Nov 22.

Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, The State University of New York, Buffalo, NY, 14214 United States. Electronic address:

Over the past few decades, monoclonal antibodies (mAbs) have become one of the most important and fastest growing classes of therapeutic molecules, with applications in a wide variety of disease areas. As such, understanding of the determinants of mAb pharmacokinetic (PK) processes (absorption, distribution, metabolism, and elimination) is crucial in developing safe and efficacious therapeutics. In the present review, we discuss the use of physiologically-based pharmacokinetic (PBPK) models as an approach to characterize the in vivo behavior of mAbs, in the context of the key PK processes that should be considered in these models. Read More

View Article
November 2018

Photo-induced tyrosine side chain fragmentation in IgG4-Fc: mechanisms and solvent isotope effects.

Mol Pharm 2018 Dec 12. Epub 2018 Dec 12.

Immunoglobulin gamma (IgG) monoclonal antibodies (mAbs) are glycoproteins that have emerged as powerful and promising protein therapeutics. During the process of production, storage and transportation, exposure to ambient light is inevitable, which can cause protein physical and chemical degradation. For mechanistic studies of photo-degradation, we have exposed IgG4-Fc to UV light. Read More

View Article
December 2018
1 Read

Production of Stabilized Antibody Fragments in the E. coli Bacterial Cytoplasm and in Transiently Transfected Mammalian Cells.

Methods Mol Biol 2019 ;1904:455-480

School of Molecular Cell Biology and Biotechnology, The George S. Wise Faculty of Life Sciences, Tel-Aviv University, Ramat Aviv, Israel.

Monoclonal antibodies (mAbs) are currently the fastest growing class of therapeutic proteins. Parallel to full-length IgG format the development of recombinant technologies provided the production of smaller recombinant antibody variants. The single-chain variable fragment (scFv) antibody is a minimal form of functional antibody comprised of the variable domains of immunoglobulin light and heavy chains connected by a flexible linker. Read More

View Article
January 2019

"BIClonals": Production of Bispecific Antibodies in IgG Format in Transiently Transfected Mammalian Cells.

Methods Mol Biol 2019 ;1904:431-454

School of Molecular Cell Biology and Biotechnology, The George S. Wise Faculty of Life Sciences, Tel-Aviv University, Ramat Aviv, Israel.

Bispecific antibodies (bsAbs) are antibodies with two binding sites directed at different antigens, enabling therapeutic strategies not possible with conventional monoclonal antibodies (mAbs). Since bispecific antibodies are regarded as promising therapeutic agents, many different bispecific design modalities have been evaluated. Many of these are based on antibody fragments or on inclusion of non-antibody components. Read More

View Article
January 2019

A Method to Detect the Binding of Hyper-Glycosylated Fragment Crystallizable (Fc) Region of Human IgG1 to Glycan Receptors.

Methods Mol Biol 2019 ;1904:417-421

Liverpool School of Tropical Medicine, Liverpool, UK.

Engineering the fragment crystallizable (Fc) of human IgG can bring improved effector functions to monoclonal antibodies and Fc-fusion-based medicines and vaccines. Such Fc-effector functions are largely controlled by posttranslational modifications (PTMs) within the Fc, including the addition of glycans that introduce structural and functional heterogeneity to this class of therapeutic. Here, we describe a detailed method to allow the detection of hyper-sialylated Fcs to glycan receptors that will facilitate the future development of new mAbs and Fc-fragment therapies and vaccines. Read More

View Article
January 2019
1 Read

Rapid Chimerization of Antibodies.

Methods Mol Biol 2019 ;1904:307-317

Department of Life Sciences, Graduate School of Arts and Sciences, The University of Tokyo, Tokyo, Japan.

We previously developed the in vitro method to generate monoclonal antibodies (mAbs) from libraries constructed with chicken B-cell line DT40 (referred to as the "ADLib system"). As the wild-type DT40 cells express immunoglobulin M (IgM), the original ADLib system provides monoclonal antibodies in chicken IgM format. For the therapeutic, diagnostic, and research purposes, the Fc regions of IgMs should be exchanged to other classes and species, for example human or murine IgG. Read More

View Article
January 2019

Refining the Quality of Monoclonal Antibodies: Grafting Unique Peptide-Binding Site in the Fab Framework.

Methods Mol Biol 2019 ;1904:293-298

Department of Molecular Medicine, Beckman Research Institute at City of Hope, Duarte, CA, USA.

Monoclonal antibodies (mAbs) are a major therapeutic modality. Grafting the meditope binding site onto mAbs, also known as meditope-enabling, can extend the usefulness of mAbs by providing an additional protein-protein interaction surface without altering the stability or antigen binding. We have previously used this site for attaching dyes, cytotoxic drugs, and entire proteins. Read More

View Article
January 2019

Antigen-Specific Human Monoclonal Antibodies from Transgenic Mice.

Methods Mol Biol 2019 ;1904:253-291

Immunology, Centro de Investigaciones Biomédicas (CINBIO), Centro de Investigación Singular de Galicia, Instituto de Investigación Sanitaria Galicia Sur, Universidad de Vigo, Vigo, Spain.

Due to the difficulties found when generating fully human monoclonal antibodies (mAbs) by the traditional method, several efforts have attempted to overcome these problems, with varying levels of success. One approach has been the development of transgenic mice carrying immunoglobulin (Ig) genes in germline configuration. The engineered mouse genome can undergo productive rearrangement in the B-cell population, with the generation of mouse B lymphocytes expressing human Ig (hIg) chains. Read More

View Article
January 2019
1 Read

Purification of Human Monoclonal Antibodies and Their Fragments.

Methods Mol Biol 2019 ;1904:163-188

ETH Zurich, Institute for Chemical and Bioengineering, Zurich, Switzerland.

This chapter summarizes the most common chromatographic mAb and mAb fragment purification methods, starting by elucidating the relevant properties of the compounds and introducing the various chromatography modes that are available and useful for this application. A focus is put on the capture step affinity and ion-exchange chromatography. Aspects of scalability play an important role in judging the suitability of the methods. Read More

View Article
January 2019

An Efficient Method to Generate Monoclonal Antibodies from Human B Cells.

Methods Mol Biol 2019 ;1904:109-145

Department of Medicine, Section of Rheumatology, The Knapp Center for Lupus and Immunology, University of Chicago, Chicago, IL, USA.

In the age of personalized medicine, an efficient method to generate monoclonal antibodies (mAbs) is essential for biomedical and immunotherapeutic research. Numerous aspects of basic B-cell biology can be studied at the monoclonal level, including B-cell development, antibody responses to infection or vaccination, and autoimmune responses. Single-cell B-cell receptor cloning allows for the rapid generation of antigen-specific mAbs in a matter of several weeks. Read More

View Article
January 2019

Cancer Immunotherapy: The Dawn of Antibody Cocktails.

Methods Mol Biol 2019 ;1904:11-51

Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.

Since the approval of the first monoclonal antibody (mAb), rituximab, for hematological malignancies, almost 30 additional mAbs have been approved in oncology. Despite remarkable advances, relatively weak responses and resistance to antibody monotherapy remain major open issue. Overcoming resistance might require combinations of drugs blocking both the major target and the emerging secondary target. Read More

View Article
January 2019

Single human B cell-derived monoclonal anti-Candida antibodies enhance phagocytosis and protect against disseminated candidiasis.

Nat Commun 2018 12 11;9(1):5288. Epub 2018 Dec 11.

School of Biosciences, University of Exeter, Geoffrey Pope Building, Exeter, EX4 4QD, UK.

The high global burden of over one million annual lethal fungal infections reflects a lack of protective vaccines, late diagnosis and inadequate chemotherapy. Here, we have generated a unique set of fully human anti-Candida monoclonal antibodies (mAbs) with diagnostic and therapeutic potential by expressing recombinant antibodies from genes cloned from the B cells of patients suffering from candidiasis. Single class switched memory B cells isolated from donors serum-positive for anti-Candida IgG were differentiated in vitro and screened against recombinant Candida albicans Hyr1 cell wall protein and whole fungal cell wall preparations. Read More

View Article
December 2018

Production and characterization of monoclonal antibodies specific for major capsid VP1 protein of trichodysplasia spinulosa associated polyomavirus.

Microbiol Immunol 2018 Dec 11. Epub 2018 Dec 11.

Department of Microbiology, Yokohama City University School of Medicine, Kanagawa 236-0004, Japan.

Trichodysplasia spinulosa associated polyomavirus (TSPyV), a newly identified polyomavirus has been implicated as a causative agent of trychodysplasia spinulosa (TS), a rare proliferative skin disease in severly immunocompromised hosts. The diagnosis using monoclonal antibodies (mAbs) has been provided as a promising tool as it offers high specificity towards specific antigen. Till there is no good mAb available for diagnosis of TS disease. Read More

View Article
December 2018
1 Read

Strategies toward rheumatoid arthritis therapy; the old and the new.

J Cell Physiol 2018 Dec 7. Epub 2018 Dec 7.

Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

Currently, medications used to treat rheumatoid arthritis (RA) are glucocorticoids (GCs) and nonsteroidal anti-inflammatory drugs (NSAIDs), predominantly used for controlling the pain and inflammation, disease-modifying antirheumatic drugs (DMARDs), administered as first-line medication for newly diagnosed RA cases, and biological therapies, used to target and inhibit specific molecules of the immune and inflammatory responses. NSAIDs and other GCs are effective in alleviating the pain, inflammation, and stiffness due to RA. DMARDs that are used for RA therapy are hydroxychloroquine, methotrexate, leflunomide, and sulfasalazine. Read More

View Article
December 2018
2 Reads

Impact of Tryptophan Oxidation in Complementarity-Determining Regions of Two Monoclonal Antibodies on Structure-Function Characterized by Hydrogen-Deuterium Exchange Mass Spectrometry and Surface Plasmon Resonance.

Pharm Res 2018 Dec 10;36(1):24. Epub 2018 Dec 10.

Biologics Development, Bristol-Myers Squibb, 311 Pennington Rocky Hill Road, Pennington, NJ, 08534, USA.

Purpose: Tryptophan's (Trp) unique hydrophobic and structural properties make it an important antigen binding motif when positioned in complementarity-determining regions (CDRs) of monoclonal antibodies (mAbs). Oxidation of Trp residues within the CDR can deleteriously impact antigen binding, particularly if the CDR conformation is altered. The goal of this study was to evaluate the conformational and functional impact of Trp oxidation for two mAb subtypes, which is essential in determining the structure-function relationship and establishing appropriate analytical control strategies during protein therapeutics development. Read More

View Article
December 2018

Fully automated zirconium-89 labeling and purification of antibodies.

J Nucl Med 2018 Dec 7. Epub 2018 Dec 7.

VU University Medical Center, Netherlands.

: Up to now dozens of monoclonal antibodies (mAbs) have been approved for clinical use and furthermore hundreds are under development. To support these developments and to facilitate a personalized medicine approach, positron emission tomography (PET) imaging and quantification of mAbs, after chelation with desferrioxamine B (DFO) and radiolabeling with zirconium-89 (Zr), has become attractive. Also the use of Zr-mAbs in (pre)clinical studies is expanding rapidly. Read More

View Article
December 2018

Expectations for Phase-Appropriate Drug Substance and Drug Product Specifications for Early-Stage Protein Therapeutics.

J Pharm Sci 2018 Dec 6. Epub 2018 Dec 6.

NBE Development, AbbVie Inc, 1 N Waukegan Road, North Chicago, IL 60064, USA. Electronic address:

Early phase specifications are established to ensure that materials used in clinical studies have appropriate product quality, reducing the risk of harm to patients. Currently, guidance is available for specification setting practices at commercial phase. With very limited data and manufacturing experience available, it is not possible to fully align to these expectations at the start of clinical trials. Read More

View Article
December 2018
1 Read

Ion channels as therapeutic antibody targets.

MAbs 2018 Dec 10:1-32. Epub 2018 Dec 10.

a TetraGenetics Inc , Arlington Massachusetts , USA.

It is now well established that antibodies have numerous potential benefits when developed as therapeutics. Here, we evaluate the technical challenges of raising antibodies to membrane-spanning proteins together with enabling technologies that may facilitate the discovery of antibody therapeutics to ion channels. Additionally, we discuss the potential targeting opportunities in the anti-ion channel antibody landscape, along with a number of case studies where functional antibodies that target ion channels have been reported. Read More

View Article
December 2018

Engineered pH-dependent recycling antibodies enhance elimination of Staphylococcal enterotoxin B superantigen in mice.

MAbs 2018 Dec 7. Epub 2018 Dec 7.

a Department of Chemical and Biological Engineering , University at Buffalo , Buffalo , New York.

A new modality in antibody engineering has emerged in which the antigen affinity is designed to be pH dependent (PHD). In particular, combining high affinity binding at neutral pH with low affinity binding at acidic pH leads to a novel antibody that can more effectively neutralize the target antigen while avoiding antibody-mediated antigen accumulation. Here, we studied how the in vivo pharmacokinetics of the superantigen, Staphylococcal enterotoxin B (SEB), is affected by an engineered antibody with pH-dependent binding. Read More

View Article
December 2018

Effective binding to protein antigens by antibodies from antibody libraries designed with enhanced protein recognition propensities.

MAbs 2018 Dec 7. Epub 2018 Dec 7.

a Genomics Research Center , Academia Sinica , Taipei , Taiwan.

Antibodies provide immune protection by recognizing antigens of diverse chemical properties, but elucidating the amino acid sequence-function relationships underlying the specificity and affinity of antibody-antigen interactions remains challenging. We designed and constructed phage-displayed synthetic antibody libraries with enriched protein antigen-recognition propensities calculated with machine learning predictors, which indicated that the designed single-chain variable fragment variants were encoded with enhanced distributions of complementarity-determining region (CDR) hot spot residues with high protein antigen recognition propensities in comparison with those in the human antibody germline sequences. Antibodies derived directly from the synthetic antibody libraries, without affinity maturation cycles comparable to those in in vivo immune systems, bound to the corresponding protein antigen through diverse conformational or linear epitopes with specificity and affinity comparable to those of the affinity-matured antibodies from in vivo immune systems. Read More

View Article
December 2018

Deamidation and isomerization liability analysis of 131 clinical-stage antibodies.

MAbs 2018 Dec 10:1-13. Epub 2018 Dec 10.

a Protein Analytics , Adimab , Lebanon , NH , USA.

Contemporary in vivo and in vitro discovery platform technologies greatly increase the odds of identifying high-affinity monoclonal antibodies (mAbs) towards essentially any desired biologically relevant epitope. Lagging discovery throughput is the ability to select for highly developable mAbs with drug-like properties early in the process. Upstream consideration of developability metrics should reduce the frequency of failures in later development stages. Read More

View Article
December 2018

Controllable Hortensia-like MnO2 Synergized with Carbon nanotubes as an Efficient Electrocatalyst for Long-term Metal-air Batteries.

ACS Appl Mater Interfaces 2018 Dec 7. Epub 2018 Dec 7.

The exploitation of a high-activity and low-cost bifunctional catalyst for oxygen reduction reaction (ORR) and oxygen evolution reaction (OER) as cathode catalyst is a research priority in metal-air batteries (MeABs). Herein, a novel bifunctional hybrid catalyst of hortensia-like MnO2 synergized with carbon nanotubes (CNTs) (MnO2/CNTs) is controllably synthesized by reasonably designing the crystal structure and morphology as well as electronic arrangement. Based on these strategies, the hybrid accelerates the reaction kinetics and avoids the change of structure. Read More

View Article
December 2018

PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer.

Biomed Pharmacother 2018 Dec 3;110:312-318. Epub 2018 Dec 3.

Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address:

Colorectal cancer (CRC), as a prominent cause of cancer-related deaths, has historically been notable worldwide and many attempts have been made to raise the overall survival of CRC patients. Immune response has long been a question of great interest in a wide range of fields such as cancer therapies and anti-tumor immunity through checkpoint inhibitors, specifically anti PD-1/ PD-L1 interaction, is a new line of research for treatment of CRC patients. Following the successful development of anti-PD-1 for melanoma, renal cell carcinoma, and non-small cell lung cancer, several clinical trials have been conducted on monoclonal antibodies (MAbs) against PD-1 in CRC. Read More

View Article
December 2018
13 Reads

The Efficacy and Safety of Anti-epidermal Growth Factor Receptor Monoclonal Antibodies in Nasopharyngeal Carcinoma: Literature-based Meta-analyses.

J Cancer 2018 31;9(23):4510-4520. Epub 2018 Oct 31.

Department of Radiation Oncology, Sun Yat-sen University Cancer Centre; State Key Laboratory of Oncology in South China; Collaborative Innovation Centre of Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, China.

Anti-epidermal growth factor receptor monoclonal antibodies (anti-EGFR mAbs), such as cetuximab and nimotuzumab have been used in the treatment of nasopharyngeal carcinoma (NPC), yet their efficacy and safety are undetermined. : We performed two meta-analyses based on systematic searches of PubMed, EMBASE, the Cochrane Library and SinoMed: comparison 1 (standard therapy plus mAbs vs. standard therapy) and comparison 2 (radiotherapy plus concurrent mAbs vs. Read More

View Article
October 2018
2 Reads
2.639 Impact Factor

The Association of Baseline Serum Tumour Markers with Outcome of Patients with Metastatic Colorectal Cancer Treated with Anti-EGFR Monoclonal Antibodies in the First Line.

J Cancer 2018 20;9(22):4255-4262. Epub 2018 Oct 20.

Department of Oncology and Radiotherapy, Medical School and University Hospital in Pilsen, Charles University, Czech Republic.

The measurement of serum tumour markers is a simple and non-invasive method for assessing the response to systemic therapies in metastatic colorectal cancer (mCRC) and estimation of prognosis. The aim of our retrospective study was to evaluate the association of baseline serum levels of carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA 19-9), thymidine kinase (TK) and tissue polypeptide specific antigen (TPS) with outcome of patients with mCRC treated with combination of chemotherapy and monoclonal antibodies against epidermal growth factor receptor (anti-EGFR mAbs) in the first line. In our study, the cohort included 102 patients treated with therapy based on anti-EGFR mAbs between years 2011 and 2017 at Department of Oncology and Radiotherapy, Medical School and University Hospital in Pilsen, Czech Republic. Read More

View Article
October 2018
3 Reads

Identification of a HIV Gp41-Specific Human Monoclonal Antibody With Potent Antibody-Dependent Cellular Cytotoxicity.

Front Immunol 2018 16;9:2613. Epub 2018 Nov 16.

AIDS Institute, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong.

Antibody-Dependent Cellular Cytotoxicity (ADCC) is a major mechanism of protection against viral infections . Identification of HIV-1-specific monoclonal antibodies (mAbs) with potent ADCC activity may help develop an effective HIV-1 vaccine. In present study, we isolated such human mAb, designated E10, from an HIV-1-infected patient sample by single B cell sorting and single cell PCR. Read More

View Article
November 2018
3 Reads

The effects of sequential enzyme modifications on structural and physicochemical properties of sweet potato starch granules.

Food Chem 2019 Mar 2;277:504-514. Epub 2018 Nov 2.

Dairy and Food Science Department, South Dakota State University, Brookings, SD 57007, USA. Electronic address:

Sweet potato starch products possess unacceptable hardness and poor transparency that in-turn reduces consumer acceptability. To expand the sweet potato starch utility with user acceptable and palatable food products herein enzyme modification has been carried out. Transglucosidase (TGAN) in combination with maltogenic α-amylase (MABS) and β-amylase (BA) appears to be advantageous to modulate sweet potato starch properties. Read More

View Article

JUNO, the receptor of sperm IZUMO1, is expressed by the human oocyte and is essential for human fertilisation.

Hum Reprod 2018 Dec 5. Epub 2018 Dec 5.

University Paris Descartes, Sorbonne Paris Cité, Faculty of Medicine, Assistance Publique-Hôpitaux de Paris, University Hospital Paris Centre, CHU Cochin, Laboratory of Histology Embryology Biology of Reproduction, 123 boulevard de Port Royal, Paris, France.

Study Question: Is JUNO protein present at the surface membrane of human oocytes and involved in the fertilisation process?

Summary Answer: JUNO protein is expressed on the plasma membrane of human oocytes and its inhibition by a monoclonal antibody completely blocks gamete fusion.

What Is Known Already: Fusion of gamete membranes is the culminating event of the fertilisation process, but its molecular mechanisms are poorly understood. Until now, three molecules have been shown to be essential: CD9 tetraspanin in the oocyte, Izumo1 protein on the sperm and Juno, its corresponding receptor on the oocyte. Read More

View Article
December 2018
2 Reads

[The Brazilian market for monoclonal antibodies used in cancer treatment].

Cad Saude Publica 2018 Nov 29;34(12):e00010918. Epub 2018 Nov 29.

Escola Nacional de Saúde Pública Sergio Arouca, Fundação Oswaldo Cruz, Rio de Janeiro, Brasil.

Monoclonal antibodies (mABs) have been indicated as an innovative technology for the treatment of some types of cancer, since they are capable of targeting and selectively killing tumor cells. However, the high costs of these therapies raise questions as to the sustainability of access. This study aimed to identify the principal characteristics of monoclonal antibodies used in cancer treatment with active marketing authorization in Brazil as of 2016. Read More

View Article
November 2018
4 Reads

Generation by phage display and characterization of drug-target complex-specific antibodies for pharmacokinetic analysis of biotherapeutics.

MAbs 2018 Dec 5:1-13. Epub 2018 Dec 5.

a Bio-Rad, Antibody Division , Puchheim , Germany.

Anti-idiotypic antibodies play an important role in pre-clinical and clinical development of therapeutic antibodies, where they are used for pharmacokinetic studies and for the development of immunogenicity assays. By using an antibody phage display library in combination with guided in vitro selection against various marketed drugs, we generated antibodies that recognize the drug only when bound to its target. We have named such specificities Type 3, to distinguish them from the anti-idiotypic antibodies that specifically detect free antibody drug or total drug. Read More

View Article
December 2018
1 Read

Antibodies to watch in 2019.

MAbs 2018 Dec 5. Epub 2018 Dec 5.

b The Antibody Society , Framingham , MA , USA.

For the past 10 years, the annual 'Antibodies to watch' articles have provided updates on key events in the late-stage development of antibody therapeutics, such as first regulatory review or approval, that occurred in the year before publication or were anticipated to occur during the year of publication. To commemorate the 10th anniversary of the article series and to celebrate the 2018 Nobel Prizes in Chemistry and in Physiology or Medicine, which were given for work that is highly relevant to antibody therapeutics research and development, we expanded the scope of the data presented to include an overview of all commercial clinical development of antibody therapeutics and approval success rates for this class of molecules. Our data indicate that: 1) antibody therapeutics are entering clinical study, and being approved, in record numbers; 2) the commercial pipeline is robust, with over 570 antibody therapeutics at various clinical phases, including 62 in late-stage clinical studies; and 3) Phase 1 to approval success rates are favorable, ranging from 17-25%, depending on the therapeutic area (cancer vs. Read More

View Article
December 2018
11 Reads

Radiochemistry in a flash: photochemical conjugation and one-pot radiolabelling of antibodies for immuno-PET.

Angew Chem Int Ed Engl 2018 Dec 5. Epub 2018 Dec 5.

Univeristy of Zürich, Department of Chemistry, Winterthurerstrasse 190, CH-8057, Zürich, SWITZERLAND.

Monoclonal antibodies (mAbs), immunoglobulin fragments and other proteins are important scaffolds in the development of radiopharmaceuticals for diagnostic immuno-positron emission tomography (immuno-PET) and targeted radioimmunotherapy (RIT). Conventional methods for radiolabelling proteins with metal ions like 68Ga, 64Cu, 89Zr, and 90Y etc require multi-step procedures involving pre-purification, functionalisation with a chelate, and subsequent radiolabelling. Standard coupling chemistries are time consuming, difficult to automate, and involve synthesis, isolation and storage of an intermediate, new molecular entity (the conjugated mAb) whose biochemical properties can differ from those of the parent protein. Read More

View Article
December 2018

Glycosylation and an amino acid insertion in the head of hemagglutinin independently affect the antigenic properties of H5N1 avian influenza viruses.

Sci China Life Sci 2018 Nov 30. Epub 2018 Nov 30.

State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, 150069, China.

Antigenic drift forces us to frequently update influenza vaccines; however, the genetic basis for antigenic variation remains largely unknown. In this study, we used clade 7.2 H5 viruses as models to explore the molecular determinants of influenza virus antigenic variation. Read More

View Article
November 2018
2 Reads

Establishment of a Chinese street rabies virus library and its application for detecting neutralizing activity.

Infect Dis Poverty 2018 Dec 5;7(1):117. Epub 2018 Dec 5.

Key Laboratory of Medical Virology, Ministry of Health, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China.

Background: The injection of rabies immune globulin (RIG) is of the utmost importance in the management of category III exposures to rabies-suspect animals. Because of the high cost and limited availability of existing RIG, one possible replacement for RIG is monoclonal antibodies (MAbs) against the rabies virus (RABV). Consequently, it is necessary to determine the neutralizing activity of the MAbs against rabies viruses, especially street rabies virus. Read More

View Article
December 2018
1 Read

Neutralizing Monoclonal Antibodies as Promising Therapeutics against Middle East Respiratory Syndrome Coronavirus Infection.

Viruses 2018 Nov 30;10(12). Epub 2018 Nov 30.

School of Health Sciences, and State Key Laboratory of Virology, Wuhan University, Wuhan 430071, China.

Since emerging in 2012, Middle East Respiratory Syndrome Coronavirus (MERS-CoV) has been a global public health threat with a high fatality rate and worldwide distribution. There are no approved vaccines or therapies for MERS until now. Passive immunotherapy with neutralizing monoclonal antibodies (mAbs) is an effective prophylactic and therapeutic reagent against emerging viruses. Read More

View Article
November 2018
3 Reads

C2 domain orientation of human immunoglobulin G in solution: Structural comparison of glycosylated and aglycosylated Fc regions using small-angle X-ray scattering.

MAbs 2018 Dec 4. Epub 2018 Dec 4.

a Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences , the University of Tokyo , Kashiwa , Chiba , Japan.

The N-linked glycan in immunoglobulin G is critical for the stability and function of the crystallizable fragment (Fc) region. Alteration of these protein properties upon the removal of the N-linked glycan has often been explained by the alteration of the C2 domain orientation in the Fc region. To confirm this hypothesis, we examined the small-angle X-ray scattering (SAXS) profile of the glycosylated Fc region (gFc) and aglycosylated Fc region (aFc) in solution. Read More

View Article
December 2018
8 Reads

HER2-targeted therapy: an emerging strategy in advanced colorectal cancer.

Expert Opin Investig Drugs 2019 Jan 9;28(1):29-38. Epub 2018 Dec 9.

a Oncology Department , Hospital Universitario 12 de Octubre , Madrid , Spain.

Introduction: Colorectal cancer (CRC) is one of the most common malignant tumors; it is a focus of research globally, but the identification of clinically actionable oncogenic drivers remains elusive. Human epidermal growth factor receptor 2 (HER2) activation is present in approximately 5% of CRC and has acquired resistance to epidermal growth factor receptor (EGFR)-targeted therapy. Early clinical trials suggest an emerging role for personalized HER2-targeted therapy in a subset of metastatic CRC. Read More

View Article
January 2019
1 Read